SAGE Therapeutics Inc (SAGE) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in SAGE Therapeutics Inc (NASDAQ:SAGE) by 57.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 193,730 shares of the biopharmaceutical company’s stock after acquiring an additional 70,962 shares during the quarter. Russell Investments Group Ltd.’s holdings in SAGE Therapeutics were worth $27,286,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in shares of SAGE Therapeutics by 58.1% during the first quarter. Dimensional Fund Advisors LP now owns 46,362 shares of the biopharmaceutical company’s stock valued at $7,468,000 after buying an additional 17,044 shares during the period. Principal Financial Group Inc. lifted its stake in shares of SAGE Therapeutics by 3.2% during the first quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock valued at $1,998,000 after buying an additional 382 shares during the period. UBS Group AG lifted its stake in shares of SAGE Therapeutics by 242.6% during the first quarter. UBS Group AG now owns 23,493 shares of the biopharmaceutical company’s stock valued at $3,785,000 after buying an additional 16,636 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of SAGE Therapeutics by 8.3% during the first quarter. The Manufacturers Life Insurance Company now owns 31,067 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 2,370 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of SAGE Therapeutics by 103.5% during the first quarter. Millennium Management LLC now owns 52,592 shares of the biopharmaceutical company’s stock valued at $8,471,000 after buying an additional 26,747 shares during the period.

Shares of SAGE stock opened at $137.55 on Friday. SAGE Therapeutics Inc has a one year low of $59.65 and a one year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million for the quarter. On average, sell-side analysts expect that SAGE Therapeutics Inc will post -7.32 earnings per share for the current fiscal year.

SAGE has been the topic of several recent analyst reports. BidaskClub downgraded shares of SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 27th. LADENBURG THALM/SH SH set a $235.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Morgan Stanley upped their price objective on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Cowen reissued a “buy” rating and set a $207.00 price objective on shares of SAGE Therapeutics in a research note on Thursday. Finally, Oppenheimer set a $170.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 29th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. SAGE Therapeutics has a consensus rating of “Buy” and a consensus price target of $204.81.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

See Also: NASDAQ Stock Market Explained

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply